J&J uses share-the-wisdom approach to spread the word on Prezcobix

Johnson & Johnson ($JNJ) is trying a new tack on the old "talk to your doctor" advice. With a new campaign for its HIV drug Prezcobix, the company is urging potential patients to snap a photo and send it to their physicians to see if the drug is right for them. It's part of an overall push to get people with HIV to share their wisdom about dealing with the disease. Report

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.